



## Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

## Kane Biotech Schedules Second Quarter 2018 Earnings Conference Call and Business Update

Aug 15 2018, 4:34 PM EDT

## Kane Biotech Achieves DTC Eligibility in the United States

Aug 14 2018, 8:00 AM EDT

## Kane Biotech Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States

Aug 9 2018, 5:06 PM EDT

## Stock Overview

Symbol	KNBIF
Exchange	OTCQB
Market Cap	5.26m
Last Price	\$0.0656
52-Week	\$0.059 - \$0.08394

05/31/2018 02:00 PM EDT

## Investor Relations

Edison Advisors  
Tirth Patel  
Vice President, Investor Relations  
295 Madison Avenue, 18th Floor  
New York, NY 10017  
T: 646-653-7035  
M: 386-295-2215  
tpatel@edisongroup.com

## Management Team

### Mark Ahrens-Townsend

President and Chief Executive Officer

### Ray Dupuis

Chief Financial Officer

### Grant Humphrey

Vice President, Sales

### Nanda Yakandawala

Senior Research Scientist

### Wendy Nachtigall

Director, Marketing

### Andrea Gordon

Director, Regulatory and Quality Control

## Kane Biotech Inc.

162-196 Innovation Drive  
Winnipeg, Manitoba R3T 2N2  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.